The DOI matches its Crossref record.
Efficacy of Midodrine vs Placebo in Neurogenic Orthostatic Hypotension: A Randomized, Double-blind Multicenter Study
Abstract
Objective. —To evaluate the efficacy of a 10-mg dose of midodrine 3 times per day in improving blood pressure (BP) and ameliorating symptoms of orthostatic hypotension in patients with neurogenic orthostatic hypotension. Midodrine hydrochloride, an α=agonist, could improve orthostatic BP by increasing vasomotor and venomotor tone. Design/Methods. —A total of 171 patients with orthostatic hypotension participated in a multicenter, randomized, placebo-controlled study. They were randomized to a 10-mg dose of midodrine or placebo 3 times per day in a 6-week study, comprising single-blind run-in (at week 1) and washout at weeks 5 and 6, with an intervening double-blind period (weeks 2 to 4). Setting. —Twenty-five centers, with most patients evaluated in referral centers. Main Outcome Measures. —The primary end points were improvement in standing systolic BP, symptoms of lightheadedness, and a global symptom relief score (by the investigator and patient separately). Results. —Nine patients were not evaluable because of noncompliance or taking concomitant vasoactive medications (3 in the midodrine group, 6 in the placebo group). In the evaluable patients, midodrine resulted in improvements in standing systolic BP at all time points (P<.001 at visits 2,3,4, and 5), in reported symptoms by the end of the second week of treatment (P=.001), and in the global symptom relief score rated by both the patient (P=.03) and the investigator (P<.001). There was no effect by center, severity of orthostatic hypotension, use of fludrocortisone or compression garments, or diagnosis. The main adverse effects were those of pilomotor reactions, urinary retention, and supine hypertension. Conclusions. —Midodrine is efficacious and safe in the treatment of neurogenic orthostatic hypotension.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Midodrine (2.5-10 mg t.i.d) was shown to be effective in three randomized placebo-controlled trials. 324-326”
From 2018 ESC Guidelines for the diagnosis and management of syncope (2018) · cites this paper as [325]
In the citing paper
“There is no doubt that midodrine increases BP both in the supine and upright posture, and ameliorates the symptoms of OH.”
From 2018 ESC Guidelines for the diagnosis and management of syncope (2018) · cites this paper as [325]
Citations
Cited by
Sorted by citations
Diabetic neuropathy: A position statement by the American Diabetes Association
Pop-Busui, R., Boulton, A. J. M., Feldman, E. L., Bril, V., Freeman, R., Malik, R. A., Sosenko, J. M., & Ziegler, D. (2017) · Diabetes Care · doi:10.2337/dc16-2042 · Cited by 2,602
Developed in collaboration with, European Heart Rhythm Association (EHRA), Heart Failure Association (HFA), and Heart Rhythm Society (HRS), societies, E. B. T. F., European Society of Emergency Medicine (EuSEM), European Federation of Internal Medicine (EFIM), European Union Geriatric Medicine Society (EUGMS), American Geriatrics Society (AGS), European Neurological Society (ENS), et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp298 · Cited by 2,040
2018 ESC Guidelines for the diagnosis and management of syncope
Brignole, M., Moya, A., de Lange, F. J., Deharo, J.-C., Elliott, P. M., Fanciulli, A., Fedorowski, A., Furlan, R., Kenny, R. A., Martín, A., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy037 · Cited by 1,951
2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope
Shen, W.-K., Sheldon, R. S., Benditt, D. G., Cohen, M. I., Forman, D. E., Goldberger, Z. D., Grubb, B. P., Hamdan, M. H., Krahn, A. D., Link, M. S., et al. (2017) · Heart Rhythm · doi:10.1016/j.hrthm.2017.03.004 · Cited by 478
“There is a dose-dependent effect, in standing blood pressure (459,460,462,463,466,467).”
BackgroundWenning, G. K., Colosimo, C., Geser, F., & Poewe, W. H. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00662-8 · Cited by 470
Gibbons, C. H., Schmidt, P., Biaggioni, I., Frazier-Mills, C., Freeman, R., Isaacson, S., Karabin, B., Kuritzky, L., Lew, M., Low, P., et al. (2017) · Journal of Neurology · doi:10.1007/s00415-016-8375-x · Cited by 455
Self-citationShen, W.-K., Sheldon, R. S., Benditt, D. G., Cohen, M. I., Forman, D. E., Goldberger, Z. D., Grubb, B. P., Hamdan, M. H., Krahn, A. D., Link, M. S., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000499 · Cited by 463
“1997 9091692 (299) Aim: Assess midodrine in neurogenic OH”
BackgroundShen, W.-K., Sheldon, R. S., Benditt, D. G., Cohen, M. I., Forman, D. E., Goldberger, Z. D., Grubb, B. P., Hamdan, M. H., Krahn, A. D., Link, M. S., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000498 · Cited by 411
Neurogenic Orthostatic Hypotension
Freeman, R. (2008) · New England Journal of Medicine · doi:10.1056/nejmcp074189 · Cited by 384
Orthostatic Hypotension in the Elderly: Diagnosis and Treatment
Gupta, V., & Lipsitz, L. A. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.02.023 · Cited by 388
Ferreira, J. J., Katzenschlager, R., Bloem, B. R., Bonuccelli, U., Burn, D. J., Deuschl, G., Dietrichs, E., Fabbrini, G., Friedman, A., Kaňovský, P., et al. (2012) · European Journal of Neurology · doi:10.1111/j.1468-1331.2012.03866.x · Cited by 359
EFNS guidelines on the diagnosis and management of orthostatic hypotension
Lahrmann, H., Cortelli, P., Hilz, M., Mathias, C. J., Struhal, W., & Tassinari, M. (2006) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01512.x · Cited by 334
2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope
Shen, W.-K., Sheldon, R. S., Benditt, D. G., Cohen, M. I., Forman, D. E., Goldberger, Z. D., Grubb, B. P., Hamdan, M. H., Krahn, A. D., Link, M. S., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.03.003 · Cited by 327
Freeman, R. L., Abuzinadah, A. R., Gibbons, C. H., Jones, P. K., Miglis, M. G., & Sinn, D.-I. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.05.079 · Cited by 286
Droxidopa for neurogenic orthostatic hypotension
Kaufmann, H., Freeman, R. L., Biaggioni, I., Low, P. A., Pedder, S. C. J., Hewitt, L. A., Mauney, J., Feirtag, M., & Mathias, C. J. (2014) · Neurology · doi:10.1212/wnl.0000000000000615 · Cited by 279
Self-citationTreatment interventions for Parkinson's disease: an evidence based assessment
Rascol, O., Goetz, C. G., Koller, W. C., Poewe, W. H., & Sampaio, C. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08520-3 · Cited by 279
Guía de práctica clínica para el diagnóstico y manejo del síncope (versión 2009)
Moya‐Mitjans, À., Sutton, R., Ammirati, F., Blanc, J., Brignole, M., Dahm, J. B., Deharo, J., Gajek, J. J., Gjesdal, K., Krahn, A. D., et al. (2009) · Revista Española de Cardiología (English Edition) · doi:10.1016/s1885-5857(09)73541-8 · Cited by 277
Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies
Palma, J., & Kaufmann, H. (2018) · Movement Disorders · doi:10.1002/mds.27344 · Cited by 258
Beh, S. C., Greenberg, B. M., Frohman, T. C., & Frohman, E. M. (2012) · Neurologic Clinics · doi:10.1016/j.ncl.2012.09.008 · Cited by 263
Non-motor symptoms in Parkinson’s disease
Park, A., & Stacy, M. A. (2009) · Journal of Neurology · doi:10.1007/s00415-009-5240-1 · Cited by 235
“Orthostatic hypotension can be treated with salt, fludrocortisone, midodrine and droxidopa [30, 33, 38].”
BackgroundManagement of neurogenic orthostatic hypotension: an update
Low, P. A., & Singer, W. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70088-7 · Cited by 224
Self-citationOrthostatic Hypotension and Falls in Older Adults: A Systematic Review and Meta-analysis
Mol, A., Hoang, P. T. S. B., Sharmin, S., Reijnierse, E. M., Wezel, R. J. A. V., Meskers, C. G. M., & Maier, A. B. (2018) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2018.11.003 · Cited by 199
Singer, W. (2003) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.74.9.1294 · Cited by 196
Preventing and treating orthostatic hypotension: As easy as A, B, C
Figueroa, J. J., Basford, J. R., & Low, P. A. (2010) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.77a.09118 · Cited by 191
Self-citationOrthostatic H ypotension in P arkinson D isease: H ow M uch Y ou F all or H ow L ow Y ou G o?
Palma, J., Gómez‐Esteban, J. C., Norcliffe‐Kaufmann, L., Martínez, J. A. B., Tijero, B., Berganzo, K., & Kaufmann, H. (2015) · Movement Disorders · doi:10.1002/mds.26079 · Cited by 186
Norepinephrine Precursor Therapy in Neurogenic Orthostatic Hypotension
Kaufmann, H., Saadia, D., Voustianiouk, A., Goldstein, D. S., Holmes, C. S., Yahr, M. D., Nardin, R. A., & Freeman, R. L. (2003) · Circulation · doi:10.1161/01.cir.0000083721.49847.d7 · Cited by 177
Multiple system atrophy: insights into a rare and debilitating movement disorder
Krismer, F., & Wenning, G. K. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.26 · Cited by 177
Horstink, M. W. I. M., TOLOSA, E. S., Bonuccelli, U., Deuschl, G., Friedman, A., Kaňovský, P., Larsen, J. O., Lees, A. J., Oertel, W. H., Poewe, W. H., et al. (2006) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01548.x · Cited by 171
Drug-Related Orthostatic Hypotension: Beyond Anti-Hypertensive Medications
Rivasi, G., Rafanelli, M., Mossello, E., Brignole, M., & Ungar, A. (2020) · Drugs & Aging · doi:10.1007/s40266-020-00796-5 · Cited by 186
Podoleanu, C., Maggi, R., Brignole, M., Croci, F., Incze, A., Solano, A., Puggioni, E., & Carasca, E. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.06.052 · Cited by 165
Shen, W.-K., Sheldon, R. S., Benditt, D. G., Cohen, M. I., Forman, D. E., Goldberger, Z. D., Grubb, B. P., Hamdan, M. H., Krahn, A. D., Link, M. S., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.03.002 · Cited by 155
“in patients with syncope due to neurogenic OH.(300-309) in patients with syncope due to neurogenic OH.”
BackgroundOrthostatic Hypotension: Mechanisms, Causes, Management
Low, P. A., & Tomalia, V. A. (2015) · Journal of Clinical Neurology · doi:10.3988/jcn.2015.11.3.220 · Cited by 149
Self-citationBiaggioni, I., Freeman, R. L., Mathias, C. J., Low, P. A., Hewitt, L. A., & Kaufmann, H. (2014) · Hypertension · doi:10.1161/hypertensionaha.114.04035 · Cited by 145
Self-citationNeurogenic orthostatic hypotension: pathophysiology, evaluation, and management
Metzler, M., Duerr, S., Granata, R., Krismer, F., Robertson, D., & Wenning, G. K. (2012) · Journal of Neurology · doi:10.1007/s00415-012-6736-7 · Cited by 139
“In two multi-centre double-blind placebocontrolled studies midodrine mediated beneficial effects that ameliorated orthostatic symptoms and increased standing blood pressure [42, 81].”
BackgroundSchoffer, K. L., Henderson, R. D., O’Maley, K. A., & O’Sullivan, J. D. (2007) · Movement Disorders · doi:10.1002/mds.21428 · Cited by 137
Angeli, P., Volpin, R., Piovan, D., et al. (1998) · Hepatology · doi:10.1002/hep.510280407 · Cited by 138
Levodopa strengths and weaknesses
Jankovic, J. J. (2002) · Neurology · doi:10.1212/wnl.58.suppl_1.s19 · Cited by 131
Midodrine for orthostatic hypotension and recurrent reflex syncope: A systematic review
Izcovich, A., González Malla, C., Manzotti, M., Catalano, H. N., & Guyatt, G. (2014) · Neurology · doi:10.1212/wnl.0000000000000815 · Cited by 131
Karas, B. J., Grubb, B. P., BOEHM, K., & Kip, K. T. (2000) · Pacing and Clinical Electrophysiology · doi:10.1111/j.1540-8159.2000.tb06760.x · Cited by 129
Orthostatic Hypotension: Management of a Complex, But Common, Medical Problem
Fedorowski, A., Ricci, F., Hamrefors, V., Sandau, K. E., Chung, T., Muldowney, J. A. S., Gopinathannair, R., & Olshansky, B. (2022) · Circulation Arrhythmia and Electrophysiology · doi:10.1161/circep.121.010573 · Cited by 142
Ramirez, C. E., Okamoto, L. E., Arnold, A. C., Gamboa, A. C., Diedrich, A., Choi, L., Raj, S. R., Robertson, D., Biaggioni, I., & Shibao, C. A. (2014) · Hypertension · doi:10.1161/hypertensionaha.114.04225 · Cited by 121
“The use of midodrine, however, is limited in some patients by adverse effects, such as pilomotor reactions, pruritus of the scalp, urinary urgency or retention, and supine hypertension.(4,27) Furthermore, previous reports have described that midodrine may not work in a subgroup of patients with autonomic failure.”
BackgroundMethodManagement of non-motor symptoms in advanced Parkinson disease
Truong, D. D., Bhidayasiri, R., & Wolters, E. C. (2007) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2007.08.015 · Cited by 120
“Randomized controlled trials in patients with neurogenic orthostatic hypotension, some of whom have PD, support the use of midodrine [31,32].”
BackgroundInvited Article: Autonomic ganglia
Vernino, S. A., Sandroni, P., Singer, W., & Low, P. A. (2008) · Neurology · doi:10.1212/01.wnl.0000312280.44805.5d · Cited by 116
Self-citationMathias, C. J., Sénard, J., Braune, S., Watson, L. P. E., Aragishi, A., Keeling, J. E., & Taylor, M. D. (2001) · Clinical Autonomic Research · doi:10.1007/bf02298955 · Cited by 115
Pathophysiology, Diagnosis, and Treatment of Orthostatic Hypotension and Vasovagal Syncope
Medow, M. S., Stewart, J. M., Sanyal, S., Mumtaz, A., Sica, D. A., & Frishman, W. H. (2007) · Cardiology in Review · doi:10.1097/crd.0b013e31815c8032 · Cited by 114
“Careful dietary instruction is also important in the nonpharmacologic management of the patient with OH.”
BackgroundInfluentialGrubb, B. P., & Karas, B. J. (1999) · Pacing and Clinical Electrophysiology · doi:10.1111/j.1540-8159.1999.tb00546.x · Cited by 107
The efficacy of midodrine hydrochloride in the treatment of children with vasovagal syncope
Qingyou, Z., Junbao, D., & Chaoshu, T. (2006) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2006.07.031 · Cited by 108
Orthostatic hypotension: A review
Joseph, A., Wanono, R., Flamant, M., & Vidal‐Petiot, E. (2017) · Néphrologie & Thérapeutique · doi:10.1016/j.nephro.2017.01.003 · Cited by 109
Management of Orthostatic Hypotension in Parkinson’s Disease
Fanciulli, A., Leys, F., Falup‐Pecurariu, C., Thijs, R. D., & Wenning, G. K. (2020) · Journal of Parkinson s Disease · doi:10.3233/jpd-202036 · Cited by 108
Orthostatic Hypotension in Parkinson Disease
Palma, J., & Kaufmann, H. (2019) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2019.09.002 · Cited by 119
Evidence-based treatment of neurogenic orthostatic hypotension and related symptoms
Eschlböck, S., Wenning, G. K., & Fanciulli, A. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1791-y · Cited by 102
Pasnoor, M., Dimachkie, M. M., Kluding, P. M., & Barohn, R. J. (2013) · Neurologic Clinics · doi:10.1016/j.ncl.2013.02.004 · Cited by 102
Evidence of Small-Fiber Polyneuropathy in Unexplained, Juvenile-Onset, Widespread Pain Syndromes
Oaklander, A. L., & Klein, M. M. (2013) · PEDIATRICS · doi:10.1542/peds.2012-2597 · Cited by 99
Wenning, G. K., & Braune, S. (2001) · CNS Drugs · doi:10.2165/00023210-200115110-00003 · Cited by 102
The treatment of neurogenic orthostatic hypotension with 3,4-DL-threo-dihydroxyphenylserine
Freeman, R. L., Landsberg, L., & Young, J. (1999) · Neurology · doi:10.1212/wnl.53.9.2151 · Cited by 98
Management of Motor and Non-Motor Symptoms in Parkinson’s Disease
Sprenger, F., & Poewe, W. H. (2013) · CNS Drugs · doi:10.1007/s40263-013-0053-2 · Cited by 109
Efficacy of treatments for orthostatic hypotension: a systematic review
Logan, I., & Witham, M. D. (2012) · Age and Ageing · doi:10.1093/ageing/afs061 · Cited by 93
Orthostatic hypotension in older people: considerations, diagnosis and management
Dani, M., Dirksen, A., Taraborrelli, P., Panagopolous, D., Torocastro, M., Sutton, R., & Lim, P. B. (2021) · Clinical Medicine · doi:10.7861/clinmed.2020-1044 · Cited by 111
Magkas, N., Tsioufis, C. P., Thomopoulos, C., Dilaveris, P., Georgiopoulos, G. A., Sanidas, E. A., Papademetriou, V., & Tousoulis, D. M. (2019) · Journal of Clinical Hypertension · doi:10.1111/jch.13521 · Cited by 100
L‐Dihydroxyphenylserine (L‐DOPS): A Norepinephrine Prodrug
Goldstein, D. S. (2006) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.2006.00189.x · Cited by 94
Recent developments in multiple system atrophy
Wenning, G. K., & Stefanova, N. (2009) · Journal of Neurology · doi:10.1007/s00415-009-5173-8 · Cited by 92
Epidemiology, Diagnosis, and Management of Neurogenic Orthostatic Hypotension
Palma, J., & Kaufmann, H. (2017) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.12478 · Cited by 90
Juraschek, S. P., Daya, N. R., Appel, L. J., Miller, E. R., McEvoy, J. W., Matsushita, K., Ballantyne, C. M., & Selvin, E. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.008884 · Cited by 90
“Moreover, the mainstays of OH treatment focus on BP augmentation and stabilization and include increased salt and fluid intake,(43) deescalation of antihypertensive medications,(44) and mineralocorticoid administration.(45,46) These could have adverse health implications if the cause of OH is CVD.”
BackgroundSaklani, P., Krahn, A. D., & Klein, G. J. (2013) · Circulation · doi:10.1161/circulationaha.112.138396 · Cited by 91
Disorders of the Autonomic Nervous System
Chelimsky, T. C., Robertson, D. M., & Chelimsky, G. G. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0434-1.00102-x · Cited by 87
Meißner, K., Distel, H., & Mitzdorf, U. (2007) · BMC Medicine · doi:10.1186/1741-7015-5-3 · Cited by 86
“In total, 34 trials [8-41] investigating chronic stable clinical conditions and reporting on at least one peripheral outcome”
BackgroundManagement of supine hypertension in patients with neurogenic orthostatic hypotension
Jordan, J., Fanciulli, A., Tank, J., Buonaura, G. C., Cheshire, W. P., Cortelli, P., Eschlboeck, S., Grassi, G. M., Hilz, M. J., Kaufmann, H., et al. (2019) · Journal of Hypertension · doi:10.1097/hjh.0000000000002078 · Cited by 88
Cardiac Autonomic Neuropathy in Type 1 and 2 Diabetes: Epidemiology, Pathophysiology, and Management
Williams, S., Raheim, S. A., Khan, M. I., Rubab, U., Kanagala, P., Zhao, S. S., Worthington, A., Brown, E. E., & Alam, U. (2022) · Clinical Therapeutics · doi:10.1016/j.clinthera.2022.09.002 · Cited by 102
Appenrodt, B., Wolf, A., Grünhage, F., et al. (2008) · Liver International · doi:10.1111/j.1478-3231.2008.01734.x · Cited by 83
Kalambokis, G. N., FOTOPOULOS, A. D., Economou, M., et al. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.09.012 · Cited by 82
Mukai, S., & Lipsitz, L. A. (2002) · Clinics in Geriatric Medicine · doi:10.1016/s0749-0690(02)00008-3 · Cited by 81
Feasibility, Utility, and Safety of Midodrine During Recovery Phase From Septic Shock
Whitson, M. R., Mo, E., Nabi, T., et al. (2016) · CHEST Journal · doi:10.1016/j.chest.2016.02.657 · Cited by 80
Chen, S., Chan, P., Sun, S., Chen, H., Zhang, B., Le, W., Liu, C., Peng, G., Tang, B., Wang, L., et al. (2016) · Translational Neurodegeneration · doi:10.1186/s40035-016-0059-z · Cited by 77
Transthyretin Cardiac Amyloidoses in Older North Americans
Dharmarajan, K., & Maurer, M. S. (2012) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2011.03868.x · Cited by 80
Ross, A. J., Ocon, A. J., Medow, M. S., & Stewart, J. M. (2014) · Clinical Science · doi:10.1042/cs20130222 · Cited by 78
“Supine hypertension is a common side effect of midodrine in other forms of OI [22], but was not experienced by any of our POTS subjects of either subtype.”
BackgroundAutonomic nervous system dysfunction in Parkinson’s disease
Zesiewicz, T. A., Baker, M. J., Wahba, M. N., & Hauser, R. A. (2003) · Current Treatment Options in Neurology · doi:10.1007/s11940-003-0005-0 · Cited by 79
Raj, S. R., & Coffin, S. T. (2013) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2012.11.004 · Cited by 81
Juraschek, S. P., Cortez, M. M., Flack, J. M., Ghazi, L., Kenny, R. A., Rahman, M., Spikes, T. A., Shibao, C. A., & Biaggioni, I. (2024) · Hypertension · doi:10.1161/hyp.0000000000000236 · Cited by 92
“These patients are characterized as having hypertension but have periods of often symptomatic drops in BP. Common but often underrecognized examples are postprandial hypotension and postexercise hypotension (see Supplemental Material SM1 for details).”
BackgroundInfluentialMidodrine for Orthostatic Hypotension: A Systematic Review and Meta-Analysis of Clinical Trials
Parsaik, A. K., Singh, B., Altayar, O., Mascarenhas, S. S., Singh, S. K., Erwin, P. J., & Murad, M. H. (2013) · Journal of General Internal Medicine · doi:10.1007/s11606-013-2520-3 · Cited by 73
“study, 23 (14 %) patients dropped out due to different adverse events such as supine hypertension, pilomotor reactions, urinary urgency and retention.(17) Wright et al.”
BackgroundMethodTreatment of Orthostatic Hypotension with Midodrine and Octreotide
Hoeldtke, R. D., Horvath, G. G., Bryner, K. D., & Hobbs, G. R. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.2.4534 · Cited by 86
Multiple system atrophy: An update
Wenning, G. K., Geser, F., Stampfer‐Kountchev, M., & Tison, F. (2003) · Movement Disorders · doi:10.1002/mds.10561 · Cited by 71
Grubb, B. P., KOSINSKI, D. J., & Kanjwal, Y. (2003) · Pacing and Clinical Electrophysiology · doi:10.1046/j.1460-9592.2003.t01-1-00155.x · Cited by 69
Santer, P., Anstey, M., Patrocínio, M. D., Wibrow, B. A., Teja, B. J., Shay, D., Shaefi, S., Parsons, C. S., Houle, T. T., Eikermann, M., et al. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-06216-x · Cited by 69
Traon, A. P., Amarenco, G., Duerr, S., Kaufmann, H., Lahrmann, H., Shaftman, S. R., Tison, F., Wenning, G. K., Goetz, C. G., Poewe, W. H., et al. (2011) · Movement Disorders · doi:10.1002/mds.23742 · Cited by 68
Smith, W. B., Wan, H., Much, D. R., Robinson, A., & Martin, P. T. (2016) · Clinical Autonomic Research · doi:10.1007/s10286-016-0363-9 · Cited by 67
The patient with supine hypertension and orthostatic hypotension: a clinical dilemma
Naschitz, J. E., Slobodin, G., Elias, N., & Rosner, I. (2006) · Postgraduate Medical Journal · doi:10.1136/pgmj.2005.037457 · Cited by 69
What is the minimum duration of head-up tilt necessary to detect orthostatic hypotension?
Gehrking, J. A., Hines, S. M., Benrud‐Larson, L. M., et al. (2005) · Clinical Autonomic Research · doi:10.1007/s10286-005-0246-y · Cited by 67
Self-citationWood, L. D. (2010) · Drugs & Aging · doi:10.2165/11318330-000000000-00000 · Cited by 68
Multiple system atrophy of the cerebellar type: Clinical state of the art
Lin, D. J., Hermann, K. L., & Schmahmann, J. D. (2014) · Movement Disorders · doi:10.1002/mds.25847 · Cited by 67
Bril, V., Breiner, A., Perkins, B. A., & Zochodne, D. W. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.028 · Cited by 80
Prajjwal, P., Sanga, H. S. F., Acharya, K., Tango, T., John, J., Rodriguez, R. S. C., Marsool, M. D. M., Sulaimanov, M., Ahmed, A., & Hussin, O. A. (2023) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000001142 · Cited by 88
Traon, A. P., Piedvache, A., Perez‐Lloret, S., Buonaura, G. C., Cock, V. C. D., Colosimo, C., Cortelli, P., Debs, R., Duerr, S., Fanciulli, A., et al. (2015) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-309999 · Cited by 64
Levine, A. R., Meyer, M. J., Bittner, E. A., Berg, S. M., Kalman, R., Stanislaus, A. B., Ryan, C., Ball, S. A., & Eikermann, M. (2013) · Journal of Critical Care · doi:10.1016/j.jcrc.2013.05.021 · Cited by 64
Efficacy and safety of midodrine hydrochloride in patients with refractory vasovagal syncope
Samniah, N., Sakaguchi, S., Lurie, K. G., Iskos, D., & Benditt, D. G. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)01594-6 · Cited by 61
Orthostatic hypotension: managing a difficult problem
Jones, P. K., Shaw, B. H., & Raj, S. R. (2015) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2015.1095090 · Cited by 62
“Midodrine has been shown to significantly increase standing blood pressures while decreasing symptoms of orthostatic intolerance [38,57,58].”
BackgroundPharmacologic options available to treat symptomatic intradialytic hypotension
Perazella, M. A. (2001) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2001.28092 · Cited by 60
Khan, M. F., & Falk, R. H. (2001) · Postgraduate Medical Journal · doi:10.1136/pmj.77.913.686 · Cited by 59
The Management of Orthostatic Hypotension in Parkinson’s Disease
Sánchez‐Ferro, Á., Benito‐León, J., & Gómez‐Esteban, J. C. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00064 · Cited by 59
Non-motor symptoms: Identification and management
Muzerengi, S., Contrafatto, D., & Chaudhuri, К. R. (2007) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(08)70048-8 · Cited by 58
Treatment of postural tachycardia syndrome: a comparison of octreotide and midodrine
Hoeldtke, R. D., Bryner, K. D., Hoeldtke, M. E., & Hobbs, G. (2006) · Clinical Autonomic Research · doi:10.1007/s10286-006-0373-0 · Cited by 57
“Midodrine is a peripheral vasoconstrictor [9], whereas octreotide mainly affects the splanchnic circulation [6].”
Background
Metadata
- Authors
- Low, P. A.
- Corresponding author
- Low, Phillip A.
- ORCID
- Low, Phillip A.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 1997-04-02
- Volume
- 277
- Issue
- 13
- Pages
- 1046
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W4294549596
- Cited by
- 425
- References
- 0
- Citations by year
- 2026: 9 · 2025: 17 · 2024: 11 · 2023: 10 · 2022: 13 · 2021: 16 · 2020: 23 · 2019: 18 · 2018: 15 · 2017: 22 · 2016: 20 · 2015: 25 · 2014: 27 · 2013: 18 · 2012: 20
- FWCI
- 8.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JAMA (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Syncope and Autonomic Disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Rate Variability and Autonomic Control
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- midodrine, neurogenic orthostatic hypotension, alpha-adrenergic agonists, blood pressure, lightheadedness, symptom relief, vascular tone, adverse effects, urinary retention, supine hypertension
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
